Literature DB >> 29152836

Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers.

J-H Kim1,2,3, A M Frantz1,2,3, A L Sarver1,3, B H Gorden Klukas2,3, M Lewellen1,2,3, T D O'Brien1,3,4,5, E B Dickerson1,2,3, J F Modiano1,2,3,5,6.   

Abstract

Non-adherent, 3-dimensional sphere formation is used as an in vitro surrogate to evaluate cellular potential for tumour initiation and self-renewal. To determine if a shared molecular program underlies the capacity for sphere formation by cells originating from diverse tumour types, we characterized molecular and functional properties of 10 independent cell lines derived from 3 ontogenetically distinct dog cancers: hemangiosarcoma, osteosarcoma and glial brain tumours. Genome-wide gene expression profiling identified tumour-of-origin-dependent patterns of adjustment to sphere formation in a uniform culture condition. However, expression of the stem/progenitor markers CD34 and CD117, resistance to cytotoxic drugs and dye efflux (side population assays) showed no association with these gene expression profiles. Instead, primary sphere-forming capacity was inversely correlated with the ability to reform secondary spheres, regardless of tumour ontogeny. Primary sphere formation seemed to be proportional to the number of pre-existing cells with sphere-forming capacity in the cell lines. Cell lines where secondary sphere formation was more proficient than primary sphere formation showed enrichment of genes involved in fatty acid synthesis and immunosuppressive cytokines. In contrast, cell lines where secondary sphere formation was approximately equivalent to or less proficient than primary sphere formation showed upregulation of CD40 and enrichment of genes involved in fatty acid oxidation. Our data suggest that in vitro sphere formation is associated with upregulation of gene clusters involved in metabolic and immunosuppressive functions, which might be necessary for self-renewal and for tumour initiation and/or tumour propagation in vivo.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer; dog; genome-wide gene expression; sphere; stem cell; tumour-initiating cell

Mesh:

Substances:

Year:  2017        PMID: 29152836      PMCID: PMC5821546          DOI: 10.1111/vco.12368

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  56 in total

1.  Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells.

Authors:  Min Wu; Andy Neilson; Amy L Swift; Rebecca Moran; James Tamagnine; Diane Parslow; Suzanne Armistead; Kristie Lemire; Jim Orrell; Jay Teich; Steve Chomicz; David A Ferrick
Journal:  Am J Physiol Cell Physiol       Date:  2006-09-13       Impact factor: 4.249

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 3.  CD40-CD40 ligand.

Authors:  C van Kooten; J Banchereau
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

4.  Identification of drug-resistant subpopulations in canine hemangiosarcoma.

Authors:  A Khammanivong; B H Gorden; A M Frantz; A J Graef; E B Dickerson
Journal:  Vet Comp Oncol       Date:  2014-08-11       Impact factor: 2.613

5.  Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.

Authors:  Milcah C Scott; Aaron L Sarver; Katherine J Gavin; Venugopal Thayanithy; David M Getzy; Robert A Newman; Gary R Cutter; Kerstin Lindblad-Toh; William C Kisseberth; Lawrence E Hunter; Subbaya Subramanian; Matthew Breen; Jaime F Modiano
Journal:  Bone       Date:  2011-05-15       Impact factor: 4.398

6.  Identification of cancer stem cells in dog glioblastoma.

Authors:  G Stoica; G Lungu; H Martini-Stoica; S Waghela; J Levine; R Smith
Journal:  Vet Pathol       Date:  2009-01-27       Impact factor: 2.221

7.  Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization.

Authors:  Brandi H Gorden; Jong-Hyuk Kim; Aaron L Sarver; Aric M Frantz; Matthew Breen; Kerstin Lindblad-Toh; Timothy D O'Brien; Leslie C Sharkey; Jaime F Modiano; Erin B Dickerson
Journal:  Am J Pathol       Date:  2014-02-11       Impact factor: 4.307

8.  Metabolic plasticity in stem cell homeostasis and differentiation.

Authors:  Clifford D L Folmes; Petras P Dzeja; Timothy J Nelson; Andre Terzic
Journal:  Cell Stem Cell       Date:  2012-11-02       Impact factor: 24.633

9.  Human fatty acid synthase: properties and molecular cloning.

Authors:  A Jayakumar; M H Tai; W Y Huang; W al-Feel; M Hsu; L Abu-Elheiga; S S Chirala; S J Wakil
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression.

Authors:  Brandi H Gorden; Jhuma Saha; Ali Khammanivong; Gary K Schwartz; Erin B Dickerson
Journal:  Vasc Cell       Date:  2014-10-01
View more
  2 in total

1.  Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.

Authors:  Jong Hyuk Kim; Kate Megquier; Rachael Thomas; Aaron L Sarver; Jung Min Song; Yoon Tae Kim; Nuojin Cheng; Ashley J Schulte; Michael A Linden; Paari Murugan; LeAnn Oseth; Colleen L Forster; Ingegerd Elvers; Ross Swofford; Jason Turner-Maier; Elinor K Karlsson; Matthew Breen; Kerstin Lindblad-Toh; Jaime F Modiano
Journal:  Mol Cancer Res       Date:  2021-03-01       Impact factor: 6.333

Review 2.  Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment.

Authors:  Kendall L Langsten; Jong Hyuk Kim; Aaron L Sarver; Mark Dewhirst; Jaime F Modiano
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.